Global News

Breaking news & current latest Canadian news headlines; national weather forecasts & predictions, local news videos, money and financial news; sports stats and scores.

https://globalnews.ca/

World’s most expensive drug approved by FDA has multimillion-dollar price tag.

File - Closeup of a pharmacist scanning a prescription.
View image in full screen

A close-up of a pharmacist scanning a prescription in a file photo.

Getty Images

The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B in the country on Tuesday — a drug called Hemgenix that boasts a one-time treatment for the blood-clotting disorder.

In doing so, the agency has put the most expensive medicine ever on the market.

At US$3.5 million per dose, Hemgenix stands as the priciest drug in the world, but drugmaker CSL Behring says the groundbreaking medicine will ultimately reduce health-care costs because patients would require fewer treatments.

“We are confident this price point will generate significant cost savings for the overall health-care system and significantly lower the economic burden of hemophilia B,” the company said, according to Reuters.

Hemophilia compromises a person’s ability to prevent bleeding and requires patients to receive frequent and expensive IV drips of Factor IX, a protein that encourages blood clotting. Small cuts or bruises can be life-threatening, and if left untreated, the condition can cause bleeding that seeps into joints and internal organs, including the brain. Hemophilia primarily affects men and is caused by a gene mutation.

Hemophilia B is the less common form of the disorder, accounting for roughly 15 per cent of those with the disease, according to the FDA. About one in 40,000 people is affected by it.

Like most medicines in the U.S., most of the cost of the new treatment will be paid by insurers — not patients — including private plans and government programs.

The FDA said that it approved Hemgenix based on two small studies. One showed a 54 per cent drop in bleeding problems over the course of a year and increased patients’ levels of Factor IX. Bloomberg reported that Hemgenix was shown to free 94 per cent of patients from time-consuming and costly transfusions to control the disease.

Hemgenix works by delivering a gene for the clotting protein to the liver, where the patient can then produce it themselves.

After decades of research, gene therapies have begun reshaping the treatment of cancers and rare inheritable diseases with medicines that can modify or correct mutations embedded in people’s genetic code. Hemgenix is the first such treatment for hemophilia in the U.S. and several other drugmakers are working on gene therapies for the more common form of the disorder, hemophilia A.

“Today’s approval provides a new treatment option for patients with hemophilia B and represents important progress in the development of innovative therapies,” said the FDA’s Dr. Peter Marks.

The agency did not specify how long the treatment works. But CSL Behring said patients should benefit — in terms of reduced bleeding and increased clotting — for years.

Earlier this year, European regulators approved a similar gene therapy for hemophilia A. That drug, from drugmaker BioMarin, is still under review at the FDA.

The FDA already has two gene therapies approved in the U.S., Zynteglo and Skysona from drugmaker Bluebird Bio. Reuters reports that Zynteglo is priced at $2.8 million and Skysona carries a price tag of $3 million.

Their approvals were met with concerns from investors about the high prices. Stocks in the biotechnology company have risen eight per cent since the first treatment was approved in August.

— With files from The Associated Press

FDAHemophiliahemophilia BMost expensive drugCSL BehringHemgenixHemophilia drugmost expensive drug everworld's most expensive drug

Journalistic standards Report an error

© 2022 Global News, a division of Corus Entertainment Inc.

Яким чином підібрати шрифт до проєкту?Як гармонійно поєднувати шрифти між собою?Де взагалі брати шрифти сьогодні?
Останні новини
Full Fauci: ‘Everybody Deserves To Have The Safety Of Good Public Health And That’s Not Happening’.

Full Fauci: ‘Everybody Deserves To Have The Safety Of Good Public Health And That’s Not Happening’.

In an interview with Meet the Press, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and the Chief Medical Adviser to President Biden, discusses the early response to Covid-19, his views on the origin of th...

Why a potential rail strike is a 'significant' concern: Rep.

Why a potential rail strike is a 'significant' concern: Rep.

Congressman Brian Fitzpatrick, R-Pa., discusses the Biden administration’s energy policy, along with the potential U.S. rail strike that could cost $2 billion a day. #foxnews Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel...

PM Rishi Sunak vows to protect the NHS at The Sun's Who Cares Wins Awards.

PM Rishi Sunak vows to protect the NHS at The Sun's Who Cares Wins Awards.

RISHI Sunak vowed to protect the NHS throughout a tough winter in a personal speech drawing on his own upbringing. He promised “record funding” to the health service, which is battling rising waiting lists, staff shortages and the ongoing Covid ba...

Full Comer Interview: 'We Already Have Many Gun Laws On The Books'.

Full Comer Interview: 'We Already Have Many Gun Laws On The Books'.

Rep. James Comer (R-Ky.) rejects calls for legislative action to address gun violence and calls for increased support for policing. Ahead of the House Speaker voter, Rep. Comer defends his support for Kevin McCarthy, during an exclusive interview ...

Neil deGrasse Tyson explains what he thinks will get humans to Mars.

Neil deGrasse Tyson explains what he thinks will get humans to Mars.

Astrophysicist Neil deGrasse Tyson reacts to a discovery on Mars and what it could mean for life beyond Earth. #CNN #News

Full Panel: ‘McCarthy Does Not Now Have The Votes To Be Elected Speaker'.

Full Panel: ‘McCarthy Does Not Now Have The Votes To Be Elected Speaker'.

Full Panel: ‘McCarthy does not now have the votes to be elected Speaker’ Susan Page, Reid Wilson, Maria Teresa Kumar and Matt Gorman join the Meet the Press roundtable to discuss Republican House leadership jockeying and former President Trump’s d...